Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,396,841

« Back to Dashboard

Which drugs does patent 7,396,841 protect, and when does it expire?

Patent 7,396,841 protects PREVACID IV and is included in one NDA.

Protection for PREVACID IV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 7,396,841

Abstract:An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a nonaqueous solvent. The injectable composition is useful as an antiulcer agent.
Inventor(s): Doen; Takayuki (Suita, JP), Nagao; Masao (Kashiba, JP), Asakawa; Naoki (Takatsuki, JP), Takechi; Nobuyuki (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:10/344,805
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Process; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms NaPREVACID IVlansoprazoleINJECTABLE;INTRAVENOUS021566-001May 27, 2004DISCNYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,396,841

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-248468Aug 18, 2000
PCT Information
PCT FiledAugust 17, 2001PCT Application Number:PCT/JP01/07075
PCT Publication Date:February 28, 2002PCT Publication Number: WO02/15908

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: